Monoclonal Antibodies in Relapsed Multiple Myeloma with Cristina Gasparetto, MD
Case Scenario 2:
January 2015
July 2016
ISB 1442 Lands FDA Orphan Drug Status for R/R Multiple Myeloma
March 22nd 2023ISB 1442, a 2+1 biparatopic bispecific antibody that has CD38 and CD47 targeting domains, has received an orphan drug designation from the FDA and is being assessed in a phase 1/2 clinical trial for patients with multiple myeloma.
Read More
BCMA Therapies Changing Treatment in Relapsed/Refractory Multiple Myeloma
March 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses how targeting patients with relapsed/refractory multiple myeloma with B-cell maturation antigens like teclistamab is changing the treatment landscape.
Read More
Multiple Myeloma Awareness Month: Advancing The Understanding of Targeted Therapies Role
March 14th 2023Multiple Myeloma expert Santhosh K Sadavish MD, discusses the importance of targeted therapies for these patients and how CAR T-cell therapy has changed the outcomes of patients who relapse after multiple lines of therapy.
Read More
2 Clarke Drive
Cranbury, NJ 08512